Aravax develops specific immunotherapies to reset the immune system's response to allergens, starting with peanut allergy. Their lead product, PVX108, uses engineered peptides to induce tolerance without causing severe reactions. Phase 1 data shows positive long-term effects, including changes in immune response and reduced risk of anaphylaxis. Founded in 2015, Aravax is headquartered in Melbourne, Australia.